



Successful Analyst Assay Training and Assay Transfers- Basics and recommendations to achieve these goals

Dr. Alexander Knorre

Head of Bioassay Department/Head of Quality Control Bioassay

Eurofins BioPharma Product Testing Munich GmbH

Overview



- 1. Method Transfer: Definition and Guidelines**
- 2. Different strategies for method transfer**
- 3. Recommendations for method transfer**
- 4. Analyst training**
- 5. Summary**

Introduction: Definition Method Transfer



Definition USP <1224> TRANSFER OF ANALYTICAL PROCEDURES

The transfer of analytical procedures (TAP), also referred to as method transfer, is the documented process that qualifies a laboratory (the receiving unit) to use an analytical test procedure that originated in another laboratory (the transferring unit), thus ensuring that the receiving unit has the procedural knowledge and ability to perform the transferred analytical procedure as intended.

Introduction: Guidelines method transfer



Guidelines:

- USP <1224>
 - WHO draft guideline
- ### 'GUIDELINES ON VALIDATION – APPENDIX 4 – ANALYTICAL METHOD VALIDATION

USP 40

General Information / <1224> Transfer of Analytical Procedures 1

<1224> TRANSFER OF ANALYTICAL PROCEDURES

INTRODUCTION

Working document QAS/16.671
June 2016
Draft document for comment



GUIDELINES ON VALIDATION – APPENDIX 4 ANALYTICAL METHOD VALIDATION (June 2016) DRAFT FOR COMMENTS

Should you have any comments on the attached text, please send these to Dr S. Kopp, Group Lead, Medicines Quality Assurance, Technologies, Standards and Norms (skopp@who.int) with a copy to Ms Marie Gaspard (mgaspard@who.int) by 30 July 2016.

Medicines Quality Assurance working documents will be sent out electronically only and will also be placed on the Medicines website for comment under "Current projects". If you do not already receive our draft working documents please let us have your email address (to hornkv@who.int) and we will add it to our electronic mailing list.

25 © World Health Organization 2016
26 All rights reserved.
27 This draft is intended for a restricted audience only, i.e. the individuals and organizations having received this draft. The draft
28 may not be reviewed, abstracted, quoted, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any
29 form or by any means outside these individuals and organizations (including the organizations' concerned staff and member
30 organizations) without the permission of the World Health Organization. The draft should not be displayed on any website.
31 Please send any request for permission to:
32 Dr Sabine Kopp, Group Lead, Medicines Quality Assurance, Technologies, Standards and Norms, Regulation of Medicines and
33 other Health Technologies, Department of Essential Medicines and Health Products, World Health Organization, CH-1211
34 Geneva 27, Switzerland. Fax: (+41 22) 791 4730; email: skopp@who.int.
35 The designations employed in the presentation of the material in this draft do not imply the expression of any opinion
36 whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its
37 authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines
38 for which there may not yet be full agreement.
39 The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended
40 by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions
41 excepted, the names of proprietary products are distinguished by initial capital letters.
42 All reasonable precautions have been taken by the World Health Organization to verify the information contained in this draft.
43 However, the printed material is being distributed without warranty of any kind, either expressed or implied. The responsibility
44 for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for
45 damages arising from its use.
46 This draft does not necessarily represent the decisions or the stated policy of the World Health Organization.
47

Introduction: Guidelines method transfer



Guidelines:

- **EU GMP Guide Volume 4 Chapter 6 Quality Control**



EUROPEAN COMMISSION
HEALTH AND CONSUMERS DIRECTORATE-GENERAL
Health systems and products
Medicinal products – quality, safety and efficacy

Brussels, 28 March 2014

EudraLex

The Rules Governing Medicinal Products in the European Union

Volume 4
EU Guidelines for
Good Manufacturing Practice for
Medicinal Products for Human and Veterinary Use

Part 1
Chapter 6: Quality Control

*Prior to transferring a test method, the **transferring site** should verify that the test method(s) comply with those as described in the Marketing Authorisation or the relevant technical dossier.*

*The **original validation** of the test method(s) should be reviewed to ensure compliance with current ICH/VICH requirements.*


*A **gap analysis** should be performed and documented to identify any supplementary validation that should be performed, prior to commencing the technical transfer process.*

Activities during method transfer



1. Kick off meeting
2. Gap analysis
3. Purchase of reagents
4. *Training**
5. Feasibility
6. *Analyst Qualification**
7. Method Transfer activity (GMP)

* optional steps



Different method transfer strategies



- a.** Method training by phone
- b.** Sending Unit SME trains Receiving Unit analysts at Sending Unit site
- c.** Sending Unit SME trains Receiving Unit analysts at Receiving Unit site
- d.** Assay co-validation performed by both Sending Unit and Receiving Unit

Different strategies – pros and cons



	Strategy	Pro	Con
A	Method training by phone	<p>Possibility to save time in case RU is an experienced lab which can the assay set up without F2F training</p> <p>Prerequisite is that SU mentions EVERYTHING (important and not considered important) during the call</p>	<p>Saved time maybe equalized afterwards in case feasibility reveals that RU is not able to perform method in a similar way as the SU</p>

SU: Sending Unit

RU: Receiving Unit

Different strategies – pros and cons



	Strategy	Pro	Con
A	Method training by phone	<p>Possibility to save time in case RU is an experienced lab which can the assay set up without F2F training</p> <p>Prerequisite is that SU mentions EVERYTHING (important and not considered important) during the call</p>	<p>Saved time maybe equalized afterwards in case feasibility reveals that RU is not able to perform method in a similar way as the SU</p>
B	Sending Unit SME trains Receiving Unit analysts at Sending Unit site	<p>SU: No travel time, less stressful due to familiar environment</p> <p>RU: Procedure can be followed and learned in original environment which facilitates feasibility at RU</p>	<p>No guarantee that assay will work at RU site even when RU analysts perform assay successfully at SU site</p>

SU: Sending Unit

RU: Receiving Unit

Different strategies – pros and cons



	Strategy	Pro	Con
A	Method training by phone	<p>Possibility to save time in case RU is an experienced lab which can the assay set up without F2F training</p> <p>Prerequisite is that SU mentions EVERYTHING (important and not considered important) during the call</p>	<p>Saved time maybe equalized afterwards in case feasibility reveals that RU is not able to perform method in a similar way as the SU</p>
B	Sending Unit SME trains Receiving Unit analysts at Sending Unit site	<p>SU: No travel time, less stressful due to familiar environment</p> <p>RU: Procedure can be followed and learned in original environment which facilitates feasibility at RU</p>	<p>No guarantee that assay will work at RU site even when RU analysts perform assay successfully at SU site</p>
C	Sending Unit SME trains Receiving Unit analysts at Receiving Unit site	<p>Depending on outcome of SU SME performing the assay at the RU lab either it is clear that assay works in new environment or troubleshooting can be done right away on site</p>	<p>SU: Travel time, can be stressful for SME as the assay has to be performed in unfamiliar environment with unknown equipment</p>

SU: Sending Unit

RU: Receiving Unit

Different strategies – pros and cons



	Strategy	Pro	Con
A	Method training by phone	<p>Possibility to save time in case RU is an experienced lab which can the assay set up without F2F training</p> <p>Prerequisite is that SU mentions EVERYTHING (important and not considered important) during the call</p>	<p>Saved time maybe equalized afterwards in case feasibility reveals that RU is not able to perform method in a similar way as the SU</p>
B	Sending Unit SME trains Receiving Unit analysts at Sending Unit site	<p>SU: No travel time, less stressful due to familiar environment</p> <p>RU: Procedure can be followed and learned in original environment which facilitates feasibility at RU</p>	<p>No guarantee that assay will work at RU site even when RU analysts perform assay successfully at SU site</p>
C	Sending Unit SME trains Receiving Unit analysts at Receiving Unit site	<p>Depending on outcome of SU SME performing the assay at the RU lab either it is clear that assay works in new environment or troubleshooting can be done right away on site</p>	<p>SU: Travel time, can be stressful for SME as the assay has to be performed in unfamiliar environment with unknown equipment</p>
D	Assay co-validation performed by both Sending Unit and Receiving Unit	<p>Saves time and efforts as only one 'validation/transfer' activity is to be carried out</p>	<p>Statistics may be more complicated</p> <p>Only applicable if both transferring and receiving unit can perform co-validation at about the same time & at the same pace</p>

Different strategies- preferred ones from a CRO's point of view



	Strategy	Pro	Con
A	Method training by phone	<p>Possibility to save time in case RU is an experienced lab which can the assay set up without F2F training</p> <p>Prerequisite is that SU mentions EVERYTHING (important and not considered important) during the call</p>	<p>Saved time maybe equalized afterwards in case feasibility reveals that RU is not able to perform method in a similar way as the SU</p>
B	Sending Unit SME trains Receiving Unit analysts at Sending Unit site	<p>SU: No travel time, less stressful due to familiar environment</p> <p>RU: Procedure can be followed and learned in original environment which facilitates feasibility at RU</p>	<p>No guarantee that assay will work at RU site even when RU analysts perform assay successfully at SU site</p>
C	Sending Unit SME trains Receiving Unit analysts at Receiving Unit site	<p>Depending on outcome of SU SME performing the assay at the RU lab either it is clear that assay works in new environment or troubleshooting can be done right away on site</p>	<p>SU: Travel time, can be stressful for SME as the assay has to be performed in unfamiliar environment with unknown equipment</p>
D	Assay co-validation performed by both Sending Unit and Receiving Unit	<p>Saves time and efforts as only one 'validation/transfer' activity is to be carried out</p>	<p>Statistics may be more complicated</p> <p>Only applicable if both transferring and receiving unit can perform co-validation at about the same time & at the same pace</p>

Recommendations for Sending Unit



- **Make a journey through time back and beam you to the start of assay establishment**
 - **Put yourself in place of the Receiving Unit: What you would need to know about this specific method**
 - **Provide history of method (we did this and this because of ...and this and that did not work)- this helps the scientist at the RU to understand better and helps in potential troubleshooting**
- **Consider clarifying all not clearly defined parts in the method SOP (e.g. way of pipetting (blow out /no blow out, tip changes, etc)- try to identify local lab understanding and ‘translate’ it for the RU**
- **Providing a ‘starter package’ (consisting of reagents which ave to be procured) to the RU may accelerate the project**

Recommendations for Receiving Unit



- **Ask ask ask – do not take things for granted as your interpretation of the method SOP may be wrong**
- **Take supply chain into consideration when ordering reagents and plastic ware (local vs overseas)**
- **Discuss any modification with the Sending Unit SME prior to implementation**
- **Plan ahead and keep the Sending Unit up to date all the time**
- **Use a project manager to support the transfer team in terms of communication and keeping track of project status**

'Transfer' of methods from R&D to an external QC lab



Recommendations:

- **Make a journey through time.....**
- **Define critical reagents**
- **Provide draft method document**
- **Provide pictures or videos if helpful for better understanding**
- **Method performance of second analyst prior to 'transfer' (robustness check)**

Analyst training at Eurofins Munich



Each new analyst has to perform the following training modules:

- **General module**
- **Pipetting module**
- **Cell culture module**
- **Assay/method training module**



General module

- Lab procedures
- Good Documentation Practices
- cGMP

Pipetting module

- Training with different multi channel pipettes: Practice serial dilutions in a mock scenario using cell culture medium including FBS
- Perform ‘pipette calibration‘ with already calibrated pipettes for practice purposes using gravimetric ISO pipette calibration method -> check accuracy and precision of pipetting

Analyst Training



Cell culture module

- **General training how to perform cell culture (watch- under supervison-solo runs)**
- **Cultivation of two training cell lines (1 suspension+ 1 adherent cell line) for a period of ~ 2 weeks**
- **Training für assay specifc cell culture according to method SOP**

Analyst Training



Assay/method training module:

- **First cell based assay: Performance of an Eurofins Munich internal potency assay prior to initiation of training of any client assay**
- **3 tiered model: Watch- under supervision- solo runs (several runs until analyst and supervisor feel comfortable); discussion of results after each run**
- **Analyst qualification under protocol followed by report**
- **Release for testing according to GMP by publishing new version of overview document (e.g. responsibility matrix)**

Summary



- **Choose assay transfer scenario which fits best to the current situation (and given timeline)**
- **Sending Unit: Put yourself in the position of the ‘other’ side and provide all relevant information**
- **Receiving Unit: Do not take things for granted as your interpretation of the method SOP may be wrong- ask!**
- **Direct and open-minded communication is a key factor for success of assay transfers**
- **Thorough training of analysts is the basis for robust assay performance**

Acknowledgements



Thank you to all members of Eurofins Munich Bioassay team !

